Evidence map›Paper›PMID 38253693›Full record

ArticleScientific reports2024

A comprehensive study for selecting optimal treatment modalities for blood cancer in a Fermatean fuzzy dynamic environment.

Dilshad Alghazzawi, Aqsa Noor, Hanan Alolaiyan, Hamiden Abd El-Wahed Khalifa, Alhanouf Alburaikan, Songsong Dai, Abdul Razaq

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Dilshad AlghazzawiDepartment of Mathematics, College of Science and Arts, King Abdul Aziz University, Rabigh, Saudi Arabia.
Aqsa NoorDivision of Science and Technology, Department of Mathematics, University of Education, Lahore, 54770, Pakistan.
Hanan AlolaiyanDepartment of Mathematics, King Saud University, Riyadh, Saudi Arabia.
Hamiden Abd El-Wahed KhalifaDepartment of Mathematics, College of Science and Arts, Qassim University, 51951, Al-Badaya, Saudi Arabia.
Alhanouf AlburaikanDepartment of Mathematics, College of Science and Arts, Qassim University, 51951, Al-Badaya, Saudi Arabia.
Songsong DaiSchool of Electronics and Information Engineering, Taizhou University, Taizhou, Zhejiang, China.
Abdul RazaqDivision of Science and Technology, Department of Mathematics, University of Education, Lahore, 54770, Pakistan. abdul.razaq@ue.edu.pk.
Cairo University · EGKing Saud University · SAQassim University · SATaizhou University · CNUniversity of Education · PKUniversity of Okara · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is characterized by uncontrolled cell proliferation, leading to cellular damage or death. Acute lymphoblastic leukemia (ALL), a kind of blood cancer, that affects lymphoid cells and is a challenging malignancy to treat. The Fermatean fuzzy set (FFS) theory is highly effective at capturing imprecision due to its capacity to incorporate extensive problem descriptions that are unclear and periodic. Within the framework of this study, two innovative aggregation operators: The Fermatean fuzzy Dynamic Weighted Averaging (FFDWA) operator and the Fermatean fuzzy Dynamic Weighted Geometric (FFDWG) operator are presented. The important attributes of these operators, providing a comprehensive elucidation of their significant special cases has been discussed in details. Moreover, these operators are utilized in the development of a systematic approach for addressing scenarios involving multiple attribute decision-making (MADM) problems with Fermatean fuzzy (FF) data. A numerical example concerning on finding the optimal treatment approach for ALL using the proposed operators, is provided. At the end, the validity and merits of the new method to illustrate by comparing it with the existing methods.

Indexed as

Hematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-LymphomaCell ProliferationHumans

Identifiers

PMID38253693
PMCPMC10803788
OpenAlexW4391103433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.